In preclinical mouse models, antagonists or neutralizing antibodies of CXCL12/CXCR4 axis as potential therapeutic reagents have been shown to reduce LN metastasis of breast cancer cells and melanoma cells [135]. The gene discussed is CXCR4; the disease is melanoma.